Abstract
Susceptibility testing by the broth dilution method showed that all the gram-positive but only some of the gram-negative bacteria tested were susceptible to the antitumor antibiotic, macromomycin (MCR; NSC 170105). The minimal inhibitory concentration for the susceptible organisms was less than 3 μg/ml. The action of MCR was bactericidal; however, at very high concentrations (50 μg/ml and above) some organisms occasionally escaped death. None of the escaped organisms was resistant to MCR. In combination with other commonly used antibiotics, MCR displayed partial synergy for Pseudomonas aeruginosa (from a minimal inhibitory concentration of >100 to 12.5 μg/ml with 100 μg of chloramphenicol per ml) and for Bacillus pumilus and Staphylococcus aureus (from 1.6 to 0.4 μg/ml and below) with polymyxin B. As with mammalian cells, 125I-labeled MCR was irreversibly bound to both gram-positive and -negative bacteria. Treatment with trypsin of the 125I-labeled MCR-exposed cells did not release the bound MCR or reverse its lethal effect. When in solution in a protective buffer at 4°C, MCR was stable for up to 45 days; at 37°C, however, 25% of its bactericidal activity was lost in 72 h. Loss of activity was enhanced 16-fold in the presence of both heated and unheated pooled human sera. Urine had no effect on the activity of MCR.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Buckmire F. L. Identification and quantitation of capsular antigen in capsulated and noncapsulated strains of Haemophilus influenzae type b by crossed-immunoelectrophoresis. Infect Immun. 1976 Jun;13(6):1733–1742. doi: 10.1128/iai.13.6.1733-1742.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Buckmire F. L., Murray R. G. Studies on the cell wall of Spirillum serpens. 1. Isolation and partial purification of the outermost cell wall layer. Can J Microbiol. 1970 Oct;16(10):1011–1022. doi: 10.1139/m70-171. [DOI] [PubMed] [Google Scholar]
- Chimura H., Ishizuka M., Hamada M., Hori S., Kimura K. A new antibiotic, macromomycin, exhibiting antitumor and antimicrobial activity. J Antibiot (Tokyo) 1968 Jan;21(1):44–49. doi: 10.7164/antibiotics.21.44. [DOI] [PubMed] [Google Scholar]
- Hardy K. G. Colicinogeny and related phenomena. Bacteriol Rev. 1975 Dec;39(4):464–515. doi: 10.1128/br.39.4.464-515.1975. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Herriott R. M., Meyer E. Y., Vogt M., Modan M. Defined medium for growth of Haemophilus influenzae. J Bacteriol. 1970 Feb;101(2):513–516. doi: 10.1128/jb.101.2.513-516.1970. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Kunimoto T., Hori M., Umezawa H. Macromomycin, an inhibitor of the membrane function of tumor cells. Cancer Res. 1972 Jun;32(6):1251–1256. [PubMed] [Google Scholar]
- Kunimoto T., Hori M., Umezawa H. Reversible binding of macromomycin, a macromolecular eptide antibiotic, to cell membranes. J Antibiot (Tokyo) 1971 Mar;24(3):203–205. doi: 10.7164/antibiotics.24.203. [DOI] [PubMed] [Google Scholar]
- Laemmli U. K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970 Aug 15;227(5259):680–685. doi: 10.1038/227680a0. [DOI] [PubMed] [Google Scholar]
- Lippman M. M., Abbott B. J. Modification of transplantability and tumor growth following treatment of L1210 leukemia and TA3Ha cells with macromomycin (NSC-170105). Cancer Chemother Rep. 1973 Nov-Dec;57(4):501–503. [PubMed] [Google Scholar]
- Lippman M. M. In vitro studies on macromomycin (NSC-170105): effects on cultured TA3Ha and L1210 cells. Cancer Chemother Rep. 1974 Mar-Apr;58(2):181–187. [PubMed] [Google Scholar]
- Lippman M. M., Laster W. R., Abbott B. J., Venditti J., Baratta M. Antitumor activity of macromomycin B (NSC 170105) against murine leukemias, melanoma, and lung carcinoma. Cancer Res. 1975 Apr;35(4):939–945. [PubMed] [Google Scholar]
- Sanders C. C., Sanders W. E., Jr Effects of procedural variations on the activity of aminoglycosides in vitro. Am J Clin Pathol. 1975 Mar;63(3):438–445. doi: 10.1093/ajcp/63.3.438. [DOI] [PubMed] [Google Scholar]
- Winkelhake J. L., Kasper D. L. Affinity chromatography of anti-meningococcal antiserum. J Immunol. 1972 Oct;109(4):824–833. [PubMed] [Google Scholar]
- Winkelhake J. L., Nicolson G. L. Aglycosylantibody. Effects of exoglycosidase treatments on autochthonous antibody survival time in the circulation. J Biol Chem. 1976 Feb 25;251(4):1074–1080. [PubMed] [Google Scholar]
- Yamashita T., Naoi N., Watanabe K. Further purification and characterization of macromomycin. J Antibiot (Tokyo) 1976 Apr;29(4):415–423. doi: 10.7164/antibiotics.29.415. [DOI] [PubMed] [Google Scholar]